Media release

Annual General Meeting of Ypsomed approves all proposals

Burgdorf, 27.06.2024, 7 a.m. – The Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) approved all proposals of the Board of Directors on 26 June 2024. Around 500 shareholders attended the event in Burgdorf. They confirmed all members of the Board of Directors in office and re-elected Gilbert Achermann as Chairman of the Board of Directors.

The shareholders of Ypsomed Holding AG approved all proposals of the Board of Directors at the Annual General Meeting on 26 June 2024.

"With this clear focus, we at Ypsomed want to concentrate in future on the many opportunities in the market for subcutaneous self-injections and on expanding our global manufacturing capacities. In addition to the expansion of production in Schwerin and the construction of two new plants in China and North America, we will also further strengthen our sites in Switzerland. For example, we are doubling our toolmaking capacity with a second toolmaking facility in Solothurn," said Simon Michel at the Annual General Meeting, confirming the Ypsomed 2030 investment program with a budget of over CHF 1.5 billion over the next five years.

The Annual General Meeting approved a dividend distribution of CHF 27.3 million. Shareholders will be paid a dividend of CHF 2.00 per share for the financial year 2023/24 (previous year: CHF 1.30), half from reserves from capital contributions and half from retained earnings. The shareholders also approved the report on non-financial matters for the first time.

The current members of the Board of Directors, Gilbert Achermann, Paul Fonteyne, Dr Martin Münchbach, Betül Susamis Unaran and Simon Michel were re-elected. The Annual General Meeting approved the re-election of Gilbert Achermann as Chairman of the Board of Directors. In addition, an amendment to the Articles of Association was approved, bringing the relevant time period for the fixed and share-based long-term remuneration of the Executive Board closer to the General Meeting of Shareholders, which will vote on the proposal.

"I would like to thank our shareholders for their trust. Ypsomed has the privilege of providing people with chronic diseases with vital therapies. I am delighted to be able to continue shaping this path", comments Gilbert Achermann on his re-election as Chairman of the Board of Directors.

The next Annual General Meeting of Ypsomed will take place on 02 July 2025.

Contact
Thomas Kutt, Investor Relations, Ypsomed Holding AG
+41 34 424 35 55, thomas.kutt@ypsomed.com

Ypsomed Group
Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens,

autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has around 2,500 employees worldwide.

Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf / Switzerland
www.ypsomed.com